05:46 PM EDT, 04/03/2024 (MT Newswires) -- MacroGenics ( MGNX ) said late Wednesday that interim safety data from the phase 2 trial of vobra duo in people with metastatic castration-resistant prostate cancer is set for end-May release after a company abstract wasn't accepted by the American Society of Clinical Oncology for presentation at a meeting starting May 31.

Interim results from the trial, including updated safety and preliminary efficacy data, are set for release by May 31, the company said. Fresh data, including radiographic progression-free survival, the trial's primary endpoint, is expected in the autumn, the company said.

In the abstract submitted to the society on Feb. 6, the company said preliminary safety results from the trial "suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability" in people with the disease.

The company's shares rose 3.9% in recent after-hours trading.

Price: 14.20, Change: +0.53, Percent Change: +3.88